TapImmune Inc. (OTCMKTS:TPIV) has registered a wild ride with sharp movements in either directions in the last one year or so. A year ago, the stock price was trading close to $2.20 per share. From there on, it started its downtrend and just in seven months registered a 52-week low of $0.12.
It was again back in this year in June, when the stock reversed its declining trend and recorded an impressive run from less than $0.20 per share to all the way to over $1.50 a share. However, the stock has once again lost its momentum and finding it hard to sustain on higher levels.
Some people that witnessed 2014’s devastating decline are experiencing a deja vu moment. The opinions are divided with some people saying that this time things are different. TapImmune was not actively involved on PR front some twelve months ago. But things changed in last one year as the company started issuing promising PRs highlighting the data of the Phase 1 clinical trials.
The PRs released in last few months stated that the company is making considerable progress with Phase I clinical trials. In fact, the company is confident to start the Phase II trials on time.
When it comes to improvement related to financials, there is a huge difference seen between today’s balance sheet and that of a year ago. Last year, there were a lot of toxic “Note’ present in TapImmune’s books. However, these notes were cleared resulting in massive dilution. The best part is the debt is now paid, and the shareholders don’t need to worry about the massive dilution anymore.
In last trading session, the stock price of TapImmune Inc. (OTCMKTS:TPIV) declined more than 9% to close the trading session at $0.830. The decline came at a share volume of 1.31 million compared to an average share volume of 1.45 million.